Atomoxetine

CHEMBL641 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
255.4 g/mol
LogP
3.7
Phase
4

A selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the prefrontal cortex to improve attention, impulse control, and hyperactivity in ADHD. Unlike stimulants, it is not a controlled substance and does not have abuse potential.

Peso Molecular

255,3500 g/mol

LogP

3,70

TPSA

21,30 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CNCC[C@@H](Oc1ccccc1C)c1ccccc1

InChI

InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1

Molecular Formula

C17H21NO

HBD / HBA

1 / 2

Ligações Rotacionáveis

6

Átomos Pesados

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the prefrontal cortex to improve attention, impulse control, and hyperactivity in ADHD. Unlike stimulants, it is not a controlled substance and does not have abuse potential.

Yes, Atomoxetine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL641. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 54841. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.